DDInter122 DDInter193
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat is strictly used to prevent, but not treat, these attacks. Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. Berotralstat was approved by the European Commission on April 30, 2021 and by Health Canada on June 06, 2022.
Berotralstat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Berotralstat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saxagliptin
Berotralstat {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Berotralstat may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Berotralstat may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Berotralstat may lead to a major life threatening interaction when taken with Cobicistat